An Open Label Study to Evaluate the Efficacy of Airgent in Treating Damaged and Wrinkled Skin

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by PerfAction Ltd..
Recruitment status was  Recruiting
Sponsor:
Information provided by:
PerfAction Ltd.
ClinicalTrials.gov Identifier:
NCT00811161
First received: December 15, 2008
Last updated: June 3, 2009
Last verified: June 2009

December 15, 2008
June 3, 2009
May 2009
February 2010   (final data collection date for primary outcome measure)
Investigator/sub investigator assessment based on direct observation and photographs compared to baseline evaluation. [ Time Frame: 3-12 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00811161 on ClinicalTrials.gov Archive Site
  • recording of adverse events. [ Time Frame: 1-3 month ] [ Designated as safety issue: Yes ]
  • Evaluate subjects' satisfactory of the treatment [ Time Frame: 1-12 month ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
An Open Label Study to Evaluate the Efficacy of Airgent in Treating Damaged and Wrinkled Skin
An Open Label Study to Evaluate the Efficacy of Airgent in Treating Damaged and Wrinkled Skin

The primary objective of this study is to Evaluate the effectiveness of treatment of wrinkles or damaged skin with the Airgent device.

The secondary objective of this study are to:

  • Evaluate subjects' satisfactory of the treatment.
  • Demonstrate the safety of the Airgent treatment by evaluation of adverse events.

Each subject will attend the clinic for the screening visit, 3 or 4 treatment visits 3-4 weeks apart, and number of follow-up visits (three at least). Evaluation of results of the performed treatments will be performed in course of the next treatment visit (prior to performance the next treatment) and at follow-up visits at 1, 3 and 6 months after the last treatment in session. Additional evaluation visits at 9 and 12 months after completion the treatment session can be performed upon decision of the investigator in case when considerable improvement is recorded during the 6-months evaluation visit.

Biopsies from up to five subjects treated for stretch marks will be collected at the time of 3-months evaluation visit, from treated and untreated zone (one of each).

Subjects will be requested to refrain from using any other method of skin rejuvenation for the entire duration of the study.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Wrinkles or Damaged Skin Condition
Device: Airgent
HA needle free injection, 3-4 treatments, 3-4 weeks apart
Experimental: needle free injector of HA
Intervention: Device: Airgent
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
April 2010
February 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Females and males in good general health 18-65 years old
  • Subject that are capable of reading, following directions, and understanding the procedure to be applied and that are obligated to forgo any other method of skin rejuvenation treatment for the entire study period.

Exclusion Criteria:

  • Medical or psychiatric conditions that can affect the subject's ability to give informed consent, or complete the study.
  • Pregnant or lactating females.
  • Other known diseases including diabetes, autoimmune disorders, epilepsy, severe migraines chronic liver or kidney
  • Disease or contagious diseases, such as HIV or hepatitis
  • Participation in a clinical trial within the last 30 days.
  • Subjects on any medication (chronic use) that would affect the characteristic of the skin (medical or hormonal), such as NSAID, blood thinning medications, immunosuppressive drugs, steroids, vitamin E supplements and Isotretinoins within one month prior to enrollment.
  • Subjects who have any form of suspicious lesion on the treatment area.
  • Subjects with history of keloid formations or hypertrophic scarring.
  • Subjects with permanent makeup/ tattoo (in the treated area).
  • Subjects with any cutaneous inflammation on the treatment area such as herpes or acne.
  • Subjects with known sensitivity to hyaluronic acid or to egg products.
  • Subjects with clotting disorders.
  • Subjects addicted to drug or alcohol.
  • Subjects who underwent any aesthetic procedure in the treated area or adjacent to it.
Both
18 Years to 65 Years
Yes
Contact: Dean D. AD-EL, MD +972 3 937 6366 deana@clalit.org.il
Israel
 
NCT00811161
AR12345
No
Dr. Dean D. AD-E/ Head, Department of Plastic Surgery & Burn Unit, Rabin Medical Center
PerfAction Ltd.
Not Provided
Principal Investigator: Dean D. AD-EL D. AD-EL, MD Rabin Medical Center
PerfAction Ltd.
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP